- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.09. | Bone Biologics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 16.09. | Bone Biologics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 08.09. | BONE BIOLOGICS CORPORATION: Bone Biologics Expands Trial Sites | 2 | GlobeNewswire (USA) | ||
| 14.08. | Bone Biologics Corp - 10-Q, Quarterly Report | 12 | SEC Filings | ||
| BONE BIOLOGICS Aktie jetzt für 0€ handeln | |||||
| 23.07. | BONE BIOLOGICS CORPORATION: Bone Biologics Issues Mid-Year Shareholder Update Highlighting Progress Across 2026 Priorities | 376 | GlobeNewswire (Europe) | BURLINGTON, Mass, July 23, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics" or the "Company"), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen | |
| 16.07. | Bone Biologics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Bone Biologics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 08.07. | Bone Biologics enters into definitive agreement for $3.0M private placement | 1 | Seeking Alpha | ||
| 08.07. | BONE BIOLOGICS CORPORATION: Bone Biologics Announces up to $9.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 213 | GlobeNewswire (Europe) | BURLINGTON, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation (Nasdaq: BBLG, BBLGW) ("Bone Biologics," or the "Company"), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen | |
| 19.05. | Bone Biologics extends rhNELL-1 protein shelf life to 29 months | 1 | Investing.com | ||
| 19.05. | Bone Biologics verlängert Haltbarkeit von Protein rhNELL-1 auf 29 Monate | 1 | Investing.com Deutsch | ||
| 14.05. | Bone Biologics Corp - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 08.01. | BONE BIOLOGICS CORPORATION: Bone Biologics Highlights 2025 Key Operational, Scientific, and Corporate Milestones and Provides 2026 Outlook | 492 | GlobeNewswire (Europe) | BURLINGTON, Mass., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen | |
| 23.12.25 | BONE BIOLOGICS CORPORATION: Bone Biologics Improves Extension of rhNELL-1 Product Shelf Life to 24 Months | 421 | GlobeNewswire (Europe) | BURLINGTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Bone Biologics Corporation ("Bone Biologics" or the "Company") (NASDAQ: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TELADOC HEALTH | 5,176 | +0,39 % | Teladoc Health Adds Contactless Vitals and Ambient AI Scribe to Virtual Visit Platform | ||
| SERNOVA BIOTHERAPEUTICS | 0,070 | +1,45 % | Sernova Biotherapeutics, Inc.: Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial | TORONTO and GERMANTOWN, Md., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics Inc. ("Sernova") (TSX: SVA) (OTC: SEOVF) (FSE/XETRA: PSHO) and Seraxis Holdings, Inc. ("Seraxis") today announced... ► Artikel lesen | |
| CERENOME | 1,504 | -3,09 % | Cerenome, Inc.: Cerenome Launches CNSide CSF Molecular Profile Tests | HOUSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) ("Cerenome" or the "Company"), today announced the commercial launch... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 2,180 | -0,91 % | Atossa Therapeutics schließt CVR-Vereinbarung für Erlöse aus FDA-Prüfgutschein | ||
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals, Inc. - 8-A12B/A, Registration of securities | ||
| TANDEM DIABETES | 14,200 | -1,39 % | Tandem Diabetes Care, Inc.: Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets | Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that Tandem Mobi, the world's smallest, durable automated insulin delivery... ► Artikel lesen | |
| CO-DIAGNOSTICS | 1,115 | 0,00 % | Co-Diagnostics Reports Second Quarter 2026 Financial Results | Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Strengthening Integrated Co-Dx PCR Platform Through Scientific... ► Artikel lesen | |
| QUIDELORTHO | 11,435 | -4,55 % | Sanjeev Sharma wird neuer Leiter Investor Relations bei QuidelOrtho | ||
| VERU | 2,460 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -5- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS75973T2006 RENALYTIX... ► Artikel lesen | |
| LIFEWARD | 6,360 | -2,00 % | Lifeward Ltd. - 8-K, Current Report | ||
| CLOVER HEALTH INVESTMENTS | 4,250 | -0,70 % | Why Is Clover Health (CLOV) Stock Soaring Today | ||
| SENSEONICS | 7,950 | -1,24 % | Beta Bionics, Inc.: Beta Bionics Announces Agreement Integrate the iLet Bionic Pancreas and mint with Senseonics' Eversense 365 | IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 0,760 | 0,00 % | Tempest Therapeutics beruft Nancy Freda-Smith in den Verwaltungsrat | ||
| NANO-X IMAGING | 0,538 | 0,00 % | Nano-X Imaging Ltd: Nanox Expands Latin American Presence with Nanox.ARC Distribution Agreement in Costa Rica | Agreement with SOLME RC, SA Marks the third Latin American market this year PETACH TIKVA, Israel, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (NASDAQ: NNOX) ("Nanox"), a leader in innovative... ► Artikel lesen | |
| IMUNON | 1,030 | +7,29 % | Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer | Enrollment momentum exceeding expectations is based on highly promising survival (OS) data and well tolerated safety profile demonstrated in the Company's large, randomized Phase II study, OVATION... ► Artikel lesen |
BONE BIOLOGICS CORP gehört der Branche Gesundheitswesen an. Der aktuelle Kurs liegt bei 0,461 Euro und damit -1,41 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BONE BIOLOGICS CORP finden Sie auf Wallstreet Online.